Mirum Pharmaceuticals Plans Supplemental New Drug Application Submission In H1 2027 To Expand Indication To Pediatric Patients Aged 6 To <12 Years.

Loading news article.

Mirum Pharmaceuticals Plans Supplemental New Drug Application Submission In H1 2027 To Expand Indication To Pediatric Patients Aged 6 To <12 Years. | WAPE

Mirum Pharmaceuticals Plans Supplemental New Drug Application Submission In H1 2027 To Expand Indication To Pediatric Patients Aged 6 To <12 Years.

Article summary

Related companies

Comments —